N/A
Completed N=4,105
Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
Primary Hypercholesterolemia · Homozygous Familial Hypercholesterolemia
Source: ClinicalTrials.gov NCT00704535 ↗
Enrolled (actual)
4,105
Serious AEs
0.1%
Results posted
Jul 2009
Primary outcomePrimary: Safety as Measured by Number of Subjects With at Least One Adverse Event — 45 subjects
Summary
The purpose of this study is to evaluate the overall safety, tolerability, and efficacy of Ezetimibe when used alone or in combination with a statin in patients with hypercholesterolemia
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety as Measured by Number of Subjects With at Least One Adverse Event |
45 | — |
| PRIMARY Safety as Measured by Number and Type of Adverse Events. |
2; 4; 1; 3; 1; 6 | — |
| PRIMARY Safety as Measured by Severity of Adverse Events as Determined by the Investigator |
49; 4; 1 | — |
| PRIMARY Safety as Measured by Adverse Event Relatedness to Study Drug as Reported by the Investigator. |
20; 8; 26 | — |
| PRIMARY Safety as Measured by Dose Adjustment Upon Incidence of an Adverse Event |
45; 6; 3 | — |
| PRIMARY Safety as Measured by Outcome of Adverse Events |
49; 2; 3 | — |
| PRIMARY Tolerability as Measured by Subject Self-assessment |
1325; 1956; 713; 54; 3; 54 | — |
| SECONDARY To Evaluate the Efficacy of Ezetimibe in Lowering Serum Cholesterol Levels 28 Days After Visit 1 (Baseline) |
-62.70 | — |
Eligibility Criteria
Inclusion Criteria
- Outpatient men or women, age 18 years and above.
- Patients with primary (heterozygous familial and non-familial) hypercholesterolemia or homozygous familial hypercholesterolemia.
Exclusion Criteria
- Known hypersensitivity to Ezetimibe.
- Moderate to severe hepatic insufficiency.
- Persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal.
- Pregnancy or lactation.
- Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine
Data sourced from ClinicalTrials.gov (NCT00704535). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.